These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 29318683)

  • 1. Prospective surveillance pilot of rivaroxaban safety within the US Food and Drug Administration Sentinel System.
    Chrischilles EA; Gagne JJ; Fireman B; Nelson J; Toh S; Shoaibi A; Reichman ME; Wang S; Nguyen M; Zhang R; Izem R; Goulding MR; Southworth MR; Graham DJ; Fuller C; Katcoff H; Woodworth T; Rogers C; Saliga R; Lin ND; McMahill-Walraven CN; Nair VP; Haynes K; Carnahan RM
    Pharmacoepidemiol Drug Saf; 2018 Mar; 27(3):263-271. PubMed ID: 29318683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2-VASc score of 1.
    Coleman CI; Turpie AGG; Bunz TJ; Eriksson D; Sood NA; Baker WL
    Eur Heart J Cardiovasc Pharmacother; 2019 Apr; 5(2):64-69. PubMed ID: 30020424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
    Coleman CI; Peacock WF; Bunz TJ; Alberts MJ
    Stroke; 2017 Aug; 48(8):2142-2149. PubMed ID: 28655814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
    Yao X; Abraham NS; Sangaralingham LR; Bellolio MF; McBane RD; Shah ND; Noseworthy PA
    J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27412905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety assessment of niacin in the US Food and Drug Administration's mini-sentinel system.
    Gagne JJ; Houstoun M; Reichman ME; Hampp C; Marshall JH; Toh S
    Pharmacoepidemiol Drug Saf; 2018 Jan; 27(1):30-37. PubMed ID: 29108128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the US Food and Drug Administration Sentinel Analysis Tools Using a Comparator with a Different Indication: Comparing the Rates of Gastrointestinal Bleeding in Warfarin and Statin Users.
    Carnahan RM; Gagne JJ; Hampp C; Leonard CE; Toh S; Fuller CC; Hennessy S; Hou L; Cocoros NM; Panucci G; Woodworth T; Cosgrove A; Iyer A; Chrischilles EA
    Pharmaceut Med; 2019 Feb; 33(1):29-43. PubMed ID: 31933271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
    Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
    Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rivaroxaban versus warfarin and dabigatran in atrial fibrillation: comparative effectiveness and safety in Danish routine care.
    Gorst-Rasmussen A; Lip GY; Bjerregaard Larsen T
    Pharmacoepidemiol Drug Saf; 2016 Nov; 25(11):1236-1244. PubMed ID: 27229855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistence and outcomes of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation.
    Wu S; Xie S; Xu Y; Que D; Yau TO; Wang L; Huang Y
    J Clin Nurs; 2019 May; 28(9-10):1839-1846. PubMed ID: 30667111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKET AF.
    Chen ST; Hellkamp AS; Becker RC; Berkowitz SD; Breithardt G; Fox KAA; Hacke W; Halperin JL; Hankey GJ; Mahaffey KW; Nessel CC; Piccini JP; Singer DE; Patel MR; Melloni C
    Eur Heart J Qual Care Clin Outcomes; 2019 Apr; 5(2):145-152. PubMed ID: 30219887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
    Coleman CI; Bunz TJ; Turpie AGG
    Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation.
    Piccini JP; Hellkamp AS; Washam JB; Becker RC; Breithardt G; Berkowitz SD; Halperin JL; Hankey GJ; Hacke W; Mahaffey KW; Nessel CC; Singer DE; Fox KA; Patel MR
    Circulation; 2016 Jan; 133(4):352-60. PubMed ID: 26673560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world evidence of stroke prevention in patients with nonvalvular atrial fibrillation in the United States: the REVISIT-US study.
    Coleman CI; Antz M; Bowrin K; Evers T; Simard EP; Bonnemeier H; Cappato R
    Curr Med Res Opin; 2016 Dec; 32(12):2047-2053. PubMed ID: 27633045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of intracranial hemorrhage (RICH) in users of oral antithrombotic drugs: Nationwide pharmacoepidemiological study.
    Gulati S; Solheim O; Carlsen SM; Øie LR; Jensberg H; Gulati AM; Madsbu MA; Giannadakis C; Jakola AS; Salvesen Ø
    PLoS One; 2018; 13(8):e0202575. PubMed ID: 30138389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort study.
    Larsen TB; Skjøth F; Kjældgaard JN; Lip GYH; Nielsen PB; Søgaard M
    Lancet Haematol; 2017 May; 4(5):e237-e244. PubMed ID: 28411120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Net clinical benefit of rivaroxaban compared with warfarin in atrial fibrillation: Results from ROCKET AF.
    Barnett AS; Cyr DD; Goodman SG; Levitan BS; Yuan Z; Hankey GJ; Singer DE; Becker RC; Breithardt G; Berkowitz SD; Halperin JL; Hacke W; Mahaffey KW; Nessel CC; Fox KAA; Patel MR; Piccini JP
    Int J Cardiol; 2018 Apr; 257():78-83. PubMed ID: 29506743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the Incidence of Major Bleeding With Rivaroxaban Use Among Nonvalvular Atrial Fibrillation Patients With Versus Without Diabetes Mellitus.
    Peacock WF; Tamayo S; Sicignano N; Hopf KP; Yuan Z; Patel M
    Am J Cardiol; 2017 Mar; 119(5):753-759. PubMed ID: 28081941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of rivaroxaban and warfarin on the risk of gastrointestinal bleeding and intracranial hemorrhage in patients with atrial fibrillation: Systematic review and meta-analysis.
    Jiang H; Jiang Y; Ma H; Zeng H; Lv J
    Clin Cardiol; 2021 Sep; 44(9):1208-1215. PubMed ID: 34302375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intracardiac Thrombus Following Rivaroxaban Treatment in a Patient with Atrial Fibrillation Associated with Rheumatic Heart Disease.
    Ohara H; Yamamoto S; Nagano K; Hashikawa K
    J Stroke Cerebrovasc Dis; 2019 Nov; 28(11):104325. PubMed ID: 31427189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative safety and effectiveness of dabigatran vs. rivaroxaban and apixaban in patients with non-valvular atrial fibrillation: a retrospective study from a large healthcare system.
    Villines TC; Ahmad A; Petrini M; Tang W; Evans A; Rush T; Thompson D; Oh K; Schwartzman E
    Eur Heart J Cardiovasc Pharmacother; 2019 Apr; 5(2):80-90. PubMed ID: 30500885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.